Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T12:05:27.417Z.
Calculation as of: 2026-10-06T12:05:27.417Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92c64d45da0f6188a1f90128b536bb11be3c3b1eef81eadefd65dadb391e1e70
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Alzamend Neuro Inc
Market Cap
$5.36M
Price/OCF Ratio
N/A
Market Cap
$6.03M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.36M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | N/A |
| Femasys Inc. (FEMY)vs › | $6.10M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
